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A B S T R A C T
The aim of the study was to evaluate the role of HLA-DRB1 (Human Leukocyte Anti-
gens) matching in corneal transplantation. Fifty-two patients were observed. Low-risk
group consisted of 28 patients and high-risk group consisted of 24 patients. All the pa-
tients and donors were tissue typed with Polymerase Chain Reaction (PCR) on the HLA-
DRB1 gen. The primary corneal disease preceding keratoplasty was keratopathia (15),
leucoma (10), keratoconus (7), Re-KPP (6), impending perforation (4), combustio cor-
neae (3), degenerative disorders (2), keratoglobus (1), keratouveitis (1), corneal maculae
(1), and corneal melting syndrome (1). The graft rejection frequency was higher in the
group of high-risk patients (29%) than in the group of low risk patients (7.1%). The re-
jection rate of compatible grafts was 37% for high risk and 2% for low risk group, while
the rejection rate of incompatible was 44% in high risk and 5% in low risk group. We can
conclude that HLA-DRB1 matching does not improve corneal graft survival.
Introduction
A transparence of cornea is a predis-
posing factor for clear and right picture
on the retina. Unfortunately, there are
many diseases that cause disturbances to
the clear cornea and lead to the loss of vi-
sion. Corneal grafting is a method of
choice in treating patients with such dis-
turbances1,2. During years, corneal trans-
plantation developed from a rough and
risky experiment into a delicate and
highly successful procedure. Today it rep-
resents one of the most successful trans-
plantation procedures, with a 2-year sur-
vival rate in more than 90% of the initial
grafts into avascular cornea3. Although
the survival rate is over 90% in uncompli-
cated cases (keratoconus, degenerative
disorders, keratoglobus, nonvascularized
leukomas) the risk of graft rejection is be-
tween 65–70% in the high risk patients
(previous graft rejection, intense vascu-
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larization of the recipient bed or previous
inflammation)3.
The extraordinary success of corneal
transplantation is attributed to the »im-
munological privilege« of the cornea and
the eye. From the immunological point of
view, problems arise if the cornea is vas-
cularized or if the recipient has a history
of graft rejections4–6.
Immunological privilege is a dynamic,
physiological process that enables the eye
to accept foreign tissue grafts for an ex-
tended, or even indefinite time. The
maintenance of the immune privilege in-
cludes integrity of the blood-ocular bar-
rier, absence of HLA class II (Human
Leukocyte Antigens) molecule in the cen-
tral cornea, phenomenon called ACAID
(Anterior Chamber Associated Immune
Deviation)7. The presence of blood-ocular
barrier prevents specific and non-specific
mediators of inflammation to gain access
into the eye. Moreover, healthy cornea
has no lymphatic drainage. Numerous
studies have proved the presence of HLA
class I antigen cells in all three corneal
layers; however, HLA class II antigens
are not normally expressed on corneal
cells except on HLA class II bearing cells
(Langerhans cells) which are absent from
the central cornea and are situated at the
corneal limbus12.
Many recent researches have dealt
with the problem of acceptance of corneal
allografts. Because of the differences in
opinions, some studies are being designed
in order to evaluate the influence of HLA
class II matching of recipient and cadaver
on the survival of corneal grafts3,4,8–11.
Patients and Methods
The research included 52 patients who
had undergone corneal transplantation
during the period 1997–1998 at the De-
partment of Ophthalmology, General
Hospital »Sveti Duh«. Thirty were men
and 22 women. They were between 15–82
years of age. Risk factors are listed in Ta-
ble 1. HLA typing was performed at the
Tissue Typing Center, Urological Clinic,
University of Zagreb, School of Medicine.
It was performed on lymphocytes of the
peripheral blood using PCR-SSOP (Poly-
merase Chain Reaction – Sequence Spe-
cific Oligo Probes). Probes used in PCR
amplification were official, claimed at the
XI International Workshop12.
After surgery, all patients were given
topical steroids (Dexamethason-Neomy-
cin) four times a day, and steroid oint-
ment two times a day for the first 2 post-
operative months. Treatment was taper-
ed according to local status.
High-risk patients (previous graft fail-
ure, inflammation, vascularization of the
graft bed) and those having signs of im-
munological reaction (decreased graft cla-
rity, endothelial precipitates, increased
corneal thickness, epithelial rejection li-
ne, vascularization, inflammation) were
treated with more invasive immunosup-
pressive regiment. If necessary, topical
steroids were used every waking hour. In
addition, patients with signs of severe re-
action were given Cyclosporin A or Me-
tilprednisolon oral or i.v. The initial dose
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TABLE 1
RISK FACTORS IN CORNEAL
TRANSPLATATION
LOCAL RISK FACTORS
Vascularization of the recipient cornea
Preceding keratoplasty in the same or
fellow eye
Preceding of the eye
Urgent surgery inflammation
Donor tissue of more than 8 mm in diameter
GENERAL RISK FACTORS
Blood transfusions
Preceding transplantations of other organs
of Cyclosporin A was 10–15 mg/kg admin-
istered for the first 10–14 days, after
which it was gradually reduced according
to local status and blood levels until the
maintenance dose of about 2–6 mg/kg gi-
ven in two divided doses was reached.
The initial dose of Metilprednisolon was
80 mg daily, and it was gradually reduced
to the maintenance dose of 4-mg daily13.
Statistical analysis was performed by

2 test and Fisher-direct test.
Results
The decision for corneal transplanta-
tion was made according to medical indi-
cations, after failure of other conservative
and surgical treatments. Patients were
divided according to corneal pathology
detailed in Table 2.
The most common diagnosis for cor-
neal grafting in our group of patients was
keratopathy (15), than leucoma (10), and
keratoconus (7). Re-keratoplasty was
needed in 6 patients, impending perfora-
tion was present in 4 cases, 2 patients
had degenerative corneal changes, 2 pa-
tients had keratoglobus cases, and 1 pa-
tient had keratouveitis. Macula of the
cornea and cornea melting syndrome
were each present in one patient. Table 3.
shows the development of graft rejection.
The success rates of corneal trans-
plantations are given in Table 5. In 38 pa-
tients corneal graft remained clear, with-
out signs of rejection. Although 5 re-
cipients showed signs of immunological
reaction, rejection was prevented by med-
ication, and transplanted cornea remai-
ned clear. In 9 patients in spite of medica-
tions corneas were rejected.
In cases of rejection (14) all the recipi-
ents underwent screening for HLA anti-
bodies in the blood. The antibodies found
in two cases were not specific for antigens
of donor corneas. As both patients be-
longed to the group of high-risk patients
(previous blood transfusions and corneal
transplantation) we concluded that the
appearance of HLA antibodies repre-
sented a risk factor in graft rejection, but
3




Corneal pathology No of
eyes %
Keratopathy 15 29%
Corneal scars 10 20%
Keratoconus 7 14%
Re-KPP 6 12%
Impending perforation 4 7%




Corneal maculae 1 2%
Corneal melting syndrome 1 2%
TABLE 3
DEVELOPMENT OF GRAFT REJECTION
Appearance of the graft No of
grafts (%)
Clear graft 73%
Signs of graft rejection 10%
Irreversible graft rejection 17%
TABLE 4
THE RATE OF GRAFT REJECTION IN THE
WHOLE (HLA-DRB1 COMPATIBLE+INCOMPATI-
BLE) GROUP COMPARED WITH THE REJEC-
















was not a reliable sign to prove the im-
munnological reaction.
After risk factors were defined, pa-
tients were divided into a high risk group
(24), and low risk group (28), in order to
enable better analysis of the transplanta-
tion success. The frequency of rejection
was analyzed according to risk factors
(separately for the high risk and low-risk
group of patients). The graft rejection fre-
quency was higher in the group of high-
risk patients (29%) than in the group of
low risk patients (7.1%). Overall frequen-
cy of rejection (high and low risk patients
together) was than compared to the fre-
quency of the incompatible patients of the
same group. In high-risk patients with-
out HLA-DRB1 matched cornea the rejec-
tion rate was 31% compared to 5.2% in
the low risk group of patients. The com-
pared data showed that HLA-DRB1 al-
lele incompatibility did not increase the
risk of graft rejection (Table 4). As we can
see in Table 5, there is no significant dif-
ference in the risk of graft rejection con-
cerning HLA-DRB1 compatibilities be-
tween the two groups: 37% compared to
44% in the high-risk group, and 2% com-
pared to 5% in the low-risk group.
Discussion
Disparity between a donor and recipi-
ent at the major histocompatibility com-
plex (HLA in humans) is a predominant
factor for allograft rejection. The recipi-
ent antibodies bound to the incompatible
HLA of donor tissue increase the risk of
accelerated allograft rejection. The major
goal in transplantation surgery is to im-
prove the donor-recipient histocompati-
bility, and to optimize the immunosupre-
sive therapy14.
The role of antigens encoded by the
HLA in corneal grafting is controver-
sial15. Some investigators claim that tis-
sue typing correlates with the improved
graft survival8, whereas others have been
unable to detect such effect3.
This is in contrast to the beneficial ef-
fects of HLA-DR matching on the sur-
vival of other vascularized organs and
may be explained by the lack of HLA anti-
gen expression by native, uninflammed
corneal tissue16.
Collaborative Corneal Transplanta-
tion Studies (CCTS) Research Group de-
signed the Crossmatch Study (CS) to as-
sess the effect of crossmatching on cor-
neal graft survival in high risk patients.
The study demonstrates that neither
HLA-A-B, nor -DR antigen matching sub-
stantially reduces the likelihood of cor-
neal graft failure8.
In CCTS study serological technique
was used, disabling the detection of dif-
ferences at the molecular level that led to
graft rejection. For that reason we used
the PCR technique in which the tissue
typing is based on DNA material, and
chose HLA-DRB1 gene, the most poly-
morphic gene in the HLA gene DRB sub-
region.
In a healthy cornea HLA class II bear-
ing cells (Langerhans cells) are not pres-
ent in the central cornea. These profes-
sional antigen-presenting cells are si-
tuated at the corneal limbus. No other
corneal cells express HLA class II anti-
gens, leading to decreased immunogeni-
city of the cornea17. Some studies have
shown that heterotopically placed cor-
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TABLE 5
GRAFT REJECTION IN HLA-DRB1 COMPATIBLE
AND INCOMPATIBLE PATIENTS OF THE HIGH















neas induce alloantigen specific cytotoxic
T cells, but fail to induce a delayed type of
hypersensitivity. However, the effect was
lost when grafted corneas contained Lan-
gerhans cells18.
In cases of vascularization (high-risk
patients) this privilege is lost and donor
cornea is infiltrated with host Langer-
hans cells that act as the Antigen Pres-
enting Cells (APC) instead of the donor
APC system and start an immunological
reaction.
Unexpectedly, Corneal Transplant
Follow-Up Study (CTFS) conducted in
Great Britain showed that HLA-DR mis-
matched corneas had a significantly re-
duced risk of rejection. The authors sug-
gested that corneal graft rejection might
be mediated by a route involving recogni-
tion of allopeptides presented to CD4+
cells on compatible HLA-DR molecules19.
This process differs from a strict defini-
tion of indirect pathway of recognition,
which requires donor allopeptides to be
processed by and presented on recipient
APC. Instead, they have presumed that
donor cells (e.g. endothelial cells) present
donor allopeptides derived from HLA
class I and minor antigens to host T cells.
Endothelial cells carrying these target
molecules are attacked by CD4+ host
cells after docking onto compatible HLA-
DR molecule. These findings have shown
the beneficial effect of HLA-A-B match-
ing but no such effect of HLA-DR match-
ing in corneal transplantations. Studies
on rats and mice have suggested a role of
CD4+ cells in corneal allograft rejec-
tion20. Sonoda et al. (1992) have shown in
an experimental model that usual im-
munogenetic rules for rejection do not ap-
ply, since minor disparate corneal grafts
have shown higher rejection rate in com-
parison to the rejection rate of major
(HLA) disparate grafts21.
Our finding that HLA-DR matching
does not improve corneal graft survival
corresponds with the results of other stu-
dies3,19. Experimental models showed
that extraordinary success of orthotopic
corneal allograft survival is sustained by
active immune regulatory system, which
is multifactorial and results from alter-
nation in both induction and expression
of immune response in the eye6.
The main goal of this research was to
find the right way to create a state of spe-
cific tolerance to prevent graft rejection,
as well as to find ways to restore ele-
ments of immune privilege in the high
risk patients, in which this privilege is
lost and consequently leads to much
higher rejection rate. Restoration of the
lost immune privilege or prevention of its
abolition should optimize acceptance of
corneal allografts. Experimental models
show that the priority should be given to
minimization of HLA class I mismatches,
until further investigations finally give
answer to the role of each HLA system in
corneal grafting.
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ULOGA HLA-DRB1 PODUDARNOSTI KOD TRANSPLANTACIJE RO@NICE
S A @ E T A K
Cilj rada bio je istra`iti ulogu HLA-DRB1 podudarnosti prilikom transplantacije
ro`nice. U istra`ivanje su uklju~ena 52 pacijenta, od kojih je 28 spadalo u nisko-rizi~nu
a 24 u visoko-rizi~nu skupinu primatelja. Davatelji i primatelji ro`nica tipizirani su
PCR metodom na HLA-DRB1 gen, te je utvr|en stupanj podudarnosti. Preoperativne
dijagnoze bile su: keratopatija (15), leucoma (10), keratoconus (7), Re-KPP (6), prije-
te}a perforacija (4), combustia (3), degenerativne bolesti (2), keratoglobus (1), kera-
touveitis (1), macula ro`nice (1) i rastapanje ro`nice (1). U~estalost odbacivanja bila je
ve}a kod primatelja rizi~ne skupine (29%), nego kod nerizi~ne skupine (7.1%). U sku-
pini HLA-DRB1 podudarnih primatelja u~estalost odbacivanja bila je 37% u skupini
visoko-rizi~nih i 2% kod nisko-rizi~nih, dok je kod HLA-DRB1 nepodudarnih prima-
telja odba~eno 44% visoko-rizi~nih i 5% nisko-rizi~nih transplantata. Rezultati su po-
kazali da podudaranje primatelja i davatelj u HLA-DRB1 lokusu nije pove}alo uspje{-
nost pre`ivljenja transplantata ro`nice.
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